ESI-MS/MS quantification of 7α-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis

Andrea De Barber, William E. Connor, Anuradha Pappu, Louise S. Merkens, Robert D. Steiner

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The genetic disorder cerebrotendinous xanthomatosis (CTX) frequently remains undiagnosed for many years. Left untreated CTX is associated with the development of cataracts, xanthomas and severe neurological dysfunction. The method routinely used to screen for CTX is GC-based measurement of elevated 5α-cholestanol from hydrolyzed plasma. A plasma test for CTX utilizing ESI-MS/MS methodology would be beneficial. Methods: Development of rapid, simple LC-ESI-MS/MS methodology to test plasma for CTX is described. Two hour Girard derivatization allowed for 7α-hydroxy-4-cholesten-3-one quantification by isotope dilution LC-ESI-MS/MS within 12 min from un-hydrolyzed affected patient plasma (5 μl). Results: Adequate sensitivity and reproducibility were achieved for quantification of 7α-hydroxy-4-cholesten-3-one, which demonstrated improved utility as a diagnostic marker of disease and to monitor treatment compared to 5α-cholestanol. The mean plasma concentration of 7α-hydroxy-4-cholesten-3-one in untreated CTX-affected patients (n = 6) was 107-fold that in unaffected subjects (n = 9), with the lowest concentration in affected patients > 10-fold the highest concentration in unaffected subjects. Conclusion: Quantification of the bile acid precursor 7α-hydroxy-4-cholesten-3-one with LC-ESI-MS/MS is a novel approach to improved diagnostic testing of plasma for CTX, amenable to high-throughput analysis and automated sample handling. Development of ESI-MS/MS methodology should make CTX testing more widely available and facilitate easier diagnosis of CTX.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalClinica Chimica Acta
Volume411
Issue number1-2
DOIs
StatePublished - Jan 4 2010

Fingerprint

Cerebrotendinous Xanthomatosis
Plasmas
Testing
Cholestanol
Bile Acids and Salts
Isotopes
Dilution
Xanthomatosis
7 alpha-hydroxy-4-cholesten-3-one
Inborn Genetic Diseases
Throughput
Cataract

Keywords

  • 7α-Hydroxy-4-cholestene-3-one
  • Bile acids
  • Cataracts
  • Chenodeoxycholic acid
  • Cholestanol
  • Derivatization
  • Diagnostic
  • Girard reagent
  • Plasma
  • Xanthoma

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

ESI-MS/MS quantification of 7α-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. / De Barber, Andrea; Connor, William E.; Pappu, Anuradha; Merkens, Louise S.; Steiner, Robert D.

In: Clinica Chimica Acta, Vol. 411, No. 1-2, 04.01.2010, p. 43-48.

Research output: Contribution to journalArticle

De Barber, Andrea ; Connor, William E. ; Pappu, Anuradha ; Merkens, Louise S. ; Steiner, Robert D. / ESI-MS/MS quantification of 7α-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. In: Clinica Chimica Acta. 2010 ; Vol. 411, No. 1-2. pp. 43-48.
@article{2c2dc9b48e8e48cfbacf840825ab35b6,
title = "ESI-MS/MS quantification of 7α-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis",
abstract = "Background: The genetic disorder cerebrotendinous xanthomatosis (CTX) frequently remains undiagnosed for many years. Left untreated CTX is associated with the development of cataracts, xanthomas and severe neurological dysfunction. The method routinely used to screen for CTX is GC-based measurement of elevated 5α-cholestanol from hydrolyzed plasma. A plasma test for CTX utilizing ESI-MS/MS methodology would be beneficial. Methods: Development of rapid, simple LC-ESI-MS/MS methodology to test plasma for CTX is described. Two hour Girard derivatization allowed for 7α-hydroxy-4-cholesten-3-one quantification by isotope dilution LC-ESI-MS/MS within 12 min from un-hydrolyzed affected patient plasma (5 μl). Results: Adequate sensitivity and reproducibility were achieved for quantification of 7α-hydroxy-4-cholesten-3-one, which demonstrated improved utility as a diagnostic marker of disease and to monitor treatment compared to 5α-cholestanol. The mean plasma concentration of 7α-hydroxy-4-cholesten-3-one in untreated CTX-affected patients (n = 6) was 107-fold that in unaffected subjects (n = 9), with the lowest concentration in affected patients > 10-fold the highest concentration in unaffected subjects. Conclusion: Quantification of the bile acid precursor 7α-hydroxy-4-cholesten-3-one with LC-ESI-MS/MS is a novel approach to improved diagnostic testing of plasma for CTX, amenable to high-throughput analysis and automated sample handling. Development of ESI-MS/MS methodology should make CTX testing more widely available and facilitate easier diagnosis of CTX.",
keywords = "7α-Hydroxy-4-cholestene-3-one, Bile acids, Cataracts, Chenodeoxycholic acid, Cholestanol, Derivatization, Diagnostic, Girard reagent, Plasma, Xanthoma",
author = "{De Barber}, Andrea and Connor, {William E.} and Anuradha Pappu and Merkens, {Louise S.} and Steiner, {Robert D.}",
year = "2010",
month = "1",
day = "4",
doi = "10.1016/j.cca.2009.09.036",
language = "English (US)",
volume = "411",
pages = "43--48",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - ESI-MS/MS quantification of 7α-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis

AU - De Barber, Andrea

AU - Connor, William E.

AU - Pappu, Anuradha

AU - Merkens, Louise S.

AU - Steiner, Robert D.

PY - 2010/1/4

Y1 - 2010/1/4

N2 - Background: The genetic disorder cerebrotendinous xanthomatosis (CTX) frequently remains undiagnosed for many years. Left untreated CTX is associated with the development of cataracts, xanthomas and severe neurological dysfunction. The method routinely used to screen for CTX is GC-based measurement of elevated 5α-cholestanol from hydrolyzed plasma. A plasma test for CTX utilizing ESI-MS/MS methodology would be beneficial. Methods: Development of rapid, simple LC-ESI-MS/MS methodology to test plasma for CTX is described. Two hour Girard derivatization allowed for 7α-hydroxy-4-cholesten-3-one quantification by isotope dilution LC-ESI-MS/MS within 12 min from un-hydrolyzed affected patient plasma (5 μl). Results: Adequate sensitivity and reproducibility were achieved for quantification of 7α-hydroxy-4-cholesten-3-one, which demonstrated improved utility as a diagnostic marker of disease and to monitor treatment compared to 5α-cholestanol. The mean plasma concentration of 7α-hydroxy-4-cholesten-3-one in untreated CTX-affected patients (n = 6) was 107-fold that in unaffected subjects (n = 9), with the lowest concentration in affected patients > 10-fold the highest concentration in unaffected subjects. Conclusion: Quantification of the bile acid precursor 7α-hydroxy-4-cholesten-3-one with LC-ESI-MS/MS is a novel approach to improved diagnostic testing of plasma for CTX, amenable to high-throughput analysis and automated sample handling. Development of ESI-MS/MS methodology should make CTX testing more widely available and facilitate easier diagnosis of CTX.

AB - Background: The genetic disorder cerebrotendinous xanthomatosis (CTX) frequently remains undiagnosed for many years. Left untreated CTX is associated with the development of cataracts, xanthomas and severe neurological dysfunction. The method routinely used to screen for CTX is GC-based measurement of elevated 5α-cholestanol from hydrolyzed plasma. A plasma test for CTX utilizing ESI-MS/MS methodology would be beneficial. Methods: Development of rapid, simple LC-ESI-MS/MS methodology to test plasma for CTX is described. Two hour Girard derivatization allowed for 7α-hydroxy-4-cholesten-3-one quantification by isotope dilution LC-ESI-MS/MS within 12 min from un-hydrolyzed affected patient plasma (5 μl). Results: Adequate sensitivity and reproducibility were achieved for quantification of 7α-hydroxy-4-cholesten-3-one, which demonstrated improved utility as a diagnostic marker of disease and to monitor treatment compared to 5α-cholestanol. The mean plasma concentration of 7α-hydroxy-4-cholesten-3-one in untreated CTX-affected patients (n = 6) was 107-fold that in unaffected subjects (n = 9), with the lowest concentration in affected patients > 10-fold the highest concentration in unaffected subjects. Conclusion: Quantification of the bile acid precursor 7α-hydroxy-4-cholesten-3-one with LC-ESI-MS/MS is a novel approach to improved diagnostic testing of plasma for CTX, amenable to high-throughput analysis and automated sample handling. Development of ESI-MS/MS methodology should make CTX testing more widely available and facilitate easier diagnosis of CTX.

KW - 7α-Hydroxy-4-cholestene-3-one

KW - Bile acids

KW - Cataracts

KW - Chenodeoxycholic acid

KW - Cholestanol

KW - Derivatization

KW - Diagnostic

KW - Girard reagent

KW - Plasma

KW - Xanthoma

UR - http://www.scopus.com/inward/record.url?scp=70449532994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449532994&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2009.09.036

DO - 10.1016/j.cca.2009.09.036

M3 - Article

VL - 411

SP - 43

EP - 48

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -